Subject area |
Rare inborn error of metabolism |
More specific subject area |
Tyrosine pathway disorder, Alkaptonuria, AKUSSI, severity, nitisinone, homogentisic acid, natural history |
Type of data |
Radar charts and box plots |
How data was acquired |
Clinical assessments including subjective pain scoring, photographs, history, ultrasound abdomen, echocardiogram, dual energy x-ray absorptiometry, x-ray spine and PET-CT scan |
Data format |
Raw data |
Experimental factors |
Observations were made over 3 years before nitisinone and over 3 years after in a cohort of patients with Alkaptonuria. |
Experimental features |
Assessments and investigations were carried out over 5 visits to derive numerical scores, which were then used to calculate the Alkaptonuria Severity Score Index (AKUSSI). |
Data source location |
National AKU Centre (NAC) in Liverpool, UK |
Data accessibility |
Data is available in this manuscript |
Related research article |
Ranganath LR, Khedr M, Milan AM, Davison AS, Hughes AT, Usher JL, Taylor S, Loftus N, Daroszewska A, West E, Jones A, Briggs M, Fisher M, McCormick M, Judd S, Vinjamuri S, Griffin R, Psarelli EE, Cox TF, Sireau N, Dillon JP, Devine JM, Hughes G, Harrold J, Barton GJ, Jarvis JC, Gallagher JA. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria:evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular Genetics and Metabolism 2018 (in press) [1]. |